Anecortave acetate
Anecortave acetate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 2 | 5 | — | — | 8 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 5 | 2 | — | 2 | 8 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 6 | 2 | — | 1 | 7 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 2 | 1 | — | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | 1 | — | — | 2 |
| Pathologic neovascularization | D009389 | — | — | — | 1 | 1 | — | — | 2 |
| Choroidal neovascularization | D020256 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 2 | — | — | — | 2 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | 2 | — | — | — | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | 1 | — | — | — | 2 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | 1 | 1 | — | — | — | 1 |
| Retinal neovascularization | D015861 | — | H35.05 | — | 1 | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
| Eye injuries | D005131 | — | S00-S09 | — | 1 | — | — | — | 1 |
| Telangiectasis | D013684 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | — | — | — | — | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | 1 | — | — | — | — | 1 |
| Posterior uveitis | D015866 | EFO_1001119 | — | 1 | — | — | — | — | 1 |
| Retinal diseases | D012164 | — | H35.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intraocular pressure | D007429 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Anecortave acetate |
| INN | anecortave |
| Description | Anecortave acetate is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | cortisone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 7753-60-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2106613 |
| ChEBI ID | — |
| PubChem CID | 111332 |
| DrugBank | DB05288 |
| UNII ID | Y0PC411K4T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use